National Cancer Institute; Cancellation of Meeting, 13559 [2010-6128]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 54 / Monday, March 22, 2010 / Notices
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Cancellation
of Meeting
Notice is hereby given of the
cancellation of the National Cancer
Institute Special Emphasis Panel, April
8, 2010, 8 a.m. to April 9, 2010, 5 p.m.,
Hilton Washington DC/Rockville Hotel,
1750 Rockville Pike, Maryland,
Rockville, MD 20852 which was
published in the Federal Register on
March 5, 2010, 75FR10295.
This FRN is cancelling the meeting
notification due to an administrative
adjustment. A new FRN will be
published to provide notification of this
meeting.
Dated: March 12, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Long Term
Outcomes of Infants Identified With
Congenital Cytomegalovirus (CMV)
Infection, Funding Opportunity
Announcement (FOA) IP10–006, Initial
Review
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
pwalker on DSK8KYBLC1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Endocrinologic and Metabolic Drugs
Advisory Committee; Notice of Meeting
ACTION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Time and Date: 12 p.m.–2 p.m., June 8,
2010 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters To Be Discussed: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘Long Term Outcomes of Infants
Identified with Congenital CMV Infection,
FOA IP10–006.’’
For More Information Contact: Gregory
Anderson, M.S., M.P.H., Scientific Review
Officer, CDC, 1600 Clifton Road, NE.,
Mailstop E60, Atlanta, GA 30333, Telephone:
(404) 498–2293.
The Director, Management Analysis and
Services Office, has been delegated the
Jkt 220001
BILLING CODE 4163–18–P
AGENCY:
BILLING CODE 4140–01–P
16:41 Mar 19, 2010
[FR Doc. 2010–6217 Filed 3–19–10; 8:45 am]
Food and Drug Administration,
HHS.
[FR Doc. 2010–6128 Filed 3–19–10; 8:45 am]
VerDate Nov<24>2008
Dated: March 15, 2010.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Endocrinologic
and Metabolic Drugs Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on May 27, 2010, from 8 a.m. to 5
p.m.
Location: The Inn and Conference
Center, University of Maryland
University College (UMUC), 3501
University Blvd. East, Adelphi, MD. The
hotel telephone number is 301–985–
7300.
Contact Person: Paul Tran, Center for
Drug Evaluation and Research (HFD–
21), Food and Drug Administration,
5600 Fishers Lane (for express delivery,
5630 Fishers Lane, rm. 1093) Rockville,
MD 20857, 301–827–7001, FAX: 301–
827–6776, e-mail:
paul.tran@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512536. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
13559
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: On May 27, 2010, the
committee will discuss the safety and
efficacy of new drug application (NDA)
22–505, EGRIFTA (tesamorelin acetate),
sterile lyophilized powder for injection,
by Theratechnologies, Inc. EGRIFTA is
an analogue (a chemical compound that
resembles another compound in
structure) of growth hormone releasing
hormone (GHRH). The proposed
indication (use) for EGRIFTA in this
application is to induce and maintain a
reduction of excess visceral abdominal
fat in human immunodeficiency virus
(HIV)-infected patients with
lipodystrophy (a condition in which
abnormal deposits of fat are seen partly
as a result of using certain drugs to treat
HIV disease).
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before May 13, 2010. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2 p.m. Those desiring to make
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before May 5, 2010. Time allotted for
each presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by May 6, 2010.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
E:\FR\FM\22MRN1.SGM
22MRN1
]]>Agencies
[Federal Register Volume 75, Number 54 (Monday, March 22, 2010)]
[Notices]
[Page 13559]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-6128]
[[Page 13559]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Cancellation of Meeting
Notice is hereby given of the cancellation of the National Cancer
Institute Special Emphasis Panel, April 8, 2010, 8 a.m. to April 9,
2010, 5 p.m., Hilton Washington DC/Rockville Hotel, 1750 Rockville
Pike, Maryland, Rockville, MD 20852 which was published in the Federal
Register on March 5, 2010, 75FR10295.
This FRN is cancelling the meeting notification due to an
administrative adjustment. A new FRN will be published to provide
notification of this meeting.
Dated: March 12, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-6128 Filed 3-19-10; 8:45 am]
BILLING CODE 4140-01-P
